MRI影像组学预测乳腺癌病理完全缓解的系统综述
汇总AUC为0.813,异质性中等(I2=46.3%)。86%的研究统计功效不足,外部验证少见,仅14%评估了临床相关亚组表现。
要点
- MRI影像组学预测pCR汇总AUC为0.813,但证据整体偏倚风险较高。
- 目前多为单中心回顾性研究,外部验证不足,临床推广需谨慎。
- 报告人口学变量不一致,缺乏亚组公平性评估,阅片报告不应依赖单一模型输出。
核心结论
- MRI影像组学模型预测乳腺癌新辅助治疗pCR展现出技术潜力,但存在明显方法学和转化局限性。
- 未来研究应优先采用前瞻性多中心设计、充足样本量、透明报告及亚组分析,以支持临床部署前的公平性评估。
研究设计与样本
- 系统综述,PROSPERO注册号CRD420251143053,检索五个电子数据库。
- 方法学质量采用METRICS评分评估,公平性与偏倚风险采用基于QUADAS-2改编的框架评价。
- 关注维度包括人口学报告、样本量充分性、验证策略及亚组表现分析。
诊断标准与关键数值
- 汇总AUC为0.813,存在中等异质性(I2=46.3%,τ2=0.081)。
- 86%的纳入研究统计功效不足,不足以支持当前模型在常规临床实践中独立使用。
- 外部验证不普遍,仅14%的研究对临床相关亚组进行了性能评估。
临床应用与阅片要点
- 影像组学模型辅助判断pCR时,应意识到现有证据多来自单中心回顾性数据,不宜仅凭模型输出修改个体化治疗决策。
- 在临床和科研报告中,应记录并关注患者人口学与临床变量,以便日后评估模型在不同亚组中的适用性。
- 解读基于MRI影像组学的pCR预测结果时,需考虑统计功效不足的问题,对阴性或阳性预测保持克制。
局限性
- 大多数纳入研究为回顾性、单中心设计,方法学异质性明显,限制了结果的普适性。
- 86%的研究统计功效不足,外部验证少见,关键人口学与临床变量报告不一致,难以全面评价模型公平性与推广性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Machine learning models based on MRI radiomics show promise for predicting pathological complete response (pCR) to neoadjuvant therapy in breast cancer, with increasing interest in clinical translation. However, uncertainties remain regarding methodological quality, generalizability, and performance across patient subgroups. This systematic review provides a comprehensive evaluation of MRI radiomics models for pCR prediction, focusing on methodological robustness, validation practices, and factors affecting equitable performance.
METHODS: The review protocol was registered with PROSPERO (Registration ID: CRD420251143053). A systematic search of five electronic databases identified studies evaluating MRI-based radiomics models for pCR prediction in breast cancer. Methodological quality was assessed using the METRICS score. Fairness and risk of bias were evaluated using a custom framework adapted from QUADAS-2, focusing on demographic reporting, sample size adequacy, validation strategy, and subgroup performance analysis.
RESULTS: Thirty-five studies met the inclusion criteria (sample sizes 55-442). Most were retrospective, single-center, and methodologically heterogeneous. Although reported discrimination was favorable (pooled AUC 0.813, moderate heterogeneity [I2 = 46.3%, τ2 = 0.081]), 86% of studies were statistically underpowered and external validation was uncommon. Only 14% evaluated performance across clinically relevant subgroups. Reporting of key demographic and clinical variables was inconsistent, limiting assessment of generalizability and equitable model performance.
CONCLUSION: MRI radiomics models for pCR prediction demonstrate technical potential but face important methodological and translational limitations. Future studies should prioritize prospective multi-center designs, adequate sample sizes, transparent reporting, and subgroup analyses. Improved demographic reporting and subgroup-specific evaluation are needed to enable robust assessment of equitable model performance before clinical deployment.
引用
- Kessler, Bobowicz, Kosno, et al. MRI radiomics for predicting pathological complete response in breast cancer: a systematic review of current evidence and limitations. Eur J Radiol. 2026. PMID: 42541995. doi:10.1016/j.ejrad.2026.113101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。